期刊
CLINICAL ENDOCRINOLOGY
卷 92, 期 1, 页码 71-76出版社
WILEY
DOI: 10.1111/cen.14120
关键词
differentiated thyroid carcinoma; immune system; lymphocyte; monocytes; sorafenib
资金
- Asan Institute for Life Sciences [2018-833]
- Asan Medical Center, Seoul, Korea
Objectives: The lymphocyte-to-monocyte ratio (LMR) reflects the status of tumour-infiltrating immune cells and host immunity. The LMR has been reported as a prognostic marker in various cancers. The present study evaluated the role of the LMR as a prognostic marker in patients with progressive radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC). Design: Retrospective cohort study. Patients: Forty patients with progressive RAIR DTC who were treated by sorafenib with available baseline complete blood cell count data. Measurements: We assessed the response rate, progression-free survival (PFS) and overall survival (OS). Results: The patients were divided into low and high LMR groups based on their baseline LMRs (<4, n = 22, 55% and >= 4, n = 18, 45%, respectively). There were no significant differences in baseline characteristics between the groups. The OS curves differed significantly based on the LMR. The median OS of the low LMR group was 24.3 months and that of the high LMR group was not reached until the end of observation period (P = .015). The PFS curves and median PFS also differed significantly based on the LMR values (P = .019). In multivariate analysis, low LMR was an independent risk factor for all-cause mortality in patients with progressive RAIR DTC (hazard ratio, 2.64; 95% confidence interval: 1.04-6.72, P = .041). Conclusion: A low LMR was associated with poor response rate, PFS and OS in patients with progressive RAIR DTC treated with sorafenib. Thus, LMR could be a simple prognostic biomarker in patients with progressive RAIR DTC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据